SG10201702913XA - Use of inhibitors of bruton's tyrosine kinase (btk) - Google Patents

Use of inhibitors of bruton's tyrosine kinase (btk)

Info

Publication number
SG10201702913XA
SG10201702913XA SG10201702913XA SG10201702913XA SG10201702913XA SG 10201702913X A SG10201702913X A SG 10201702913XA SG 10201702913X A SG10201702913X A SG 10201702913XA SG 10201702913X A SG10201702913X A SG 10201702913XA SG 10201702913X A SG10201702913X A SG 10201702913XA
Authority
SG
Singapore
Prior art keywords
bruton
btk
inhibitors
tyrosine kinase
tyrosine
Prior art date
Application number
SG10201702913XA
Inventor
Joseph J Buggy
Laurence Elias
Gwen Fyfe
Eric Hedrick
David J Loury
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of SG10201702913XA publication Critical patent/SG10201702913XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
SG10201702913XA 2011-10-19 2012-10-19 Use of inhibitors of bruton's tyrosine kinase (btk) SG10201702913XA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161549067P 2011-10-19 2011-10-19

Publications (1)

Publication Number Publication Date
SG10201702913XA true SG10201702913XA (en) 2017-06-29

Family

ID=48141634

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201401625TA SG11201401625TA (en) 2011-10-19 2012-10-19 Use of inhibitors of bruton's tyrosine kinase (btk)
SG10201702913XA SG10201702913XA (en) 2011-10-19 2012-10-19 Use of inhibitors of bruton's tyrosine kinase (btk)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201401625TA SG11201401625TA (en) 2011-10-19 2012-10-19 Use of inhibitors of bruton's tyrosine kinase (btk)

Country Status (13)

Country Link
US (3) US20140303191A1 (en)
EP (1) EP2771010A4 (en)
JP (5) JP6506555B2 (en)
KR (4) KR102258778B1 (en)
CN (2) CN110801454A (en)
AU (4) AU2012325804B2 (en)
BR (1) BR112014009276A8 (en)
CA (2) CA3110966A1 (en)
EA (2) EA201892766A1 (en)
IL (3) IL232059B (en)
MX (1) MX361772B (en)
SG (2) SG11201401625TA (en)
WO (1) WO2013059738A2 (en)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
RU2536584C2 (en) 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Heteroaryl compounds and using them
EP3311818A3 (en) 2008-07-16 2018-07-18 Pharmacyclics, LLC Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
KR101705158B1 (en) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Egfr inhibitors and methods of treating diseases
SG185617A1 (en) 2010-05-31 2012-12-28 Ono Pharmaceutical Co Purinone derivative
CN107898791A (en) 2010-06-03 2018-04-13 药品循环有限责任公司 The application of bruton's tyrosine kinase (BTK) inhibitor
US8563568B2 (en) 2010-08-10 2013-10-22 Celgene Avilomics Research, Inc. Besylate salt of a BTK inhibitor
JP5956999B2 (en) 2010-11-01 2016-07-27 セルジーン アヴィロミクス リサーチ， インコーポレイテッド Heteroaryl compounds and uses thereof
CN103269704B (en) 2010-11-01 2018-07-06 西建卡尔有限责任公司 Heterocyclic compound and its purposes
ES2665013T3 (en) 2010-11-10 2018-04-24 Celgene Car Llc EGFR selective mutant inhibitors and uses thereof
TWI674262B (en) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 Processes for preparing isoquinolinones and solid forms of isoquinolinones
CA2836410C (en) 2011-05-17 2019-08-20 Principia Biopharma Inc. Tyrosine kinase inhibitors
WO2012158795A1 (en) 2011-05-17 2012-11-22 Principia Biopharma Inc. Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
US9233111B2 (en) 2011-07-08 2016-01-12 Novartis Ag Pyrrolo pyrimidine derivatives
KR20140048968A (en) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 Inhibitors of bruton's tyrosine kinase
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
CN103889987B (en) 2011-07-19 2016-09-14 默沙东有限责任公司 Imidazopyrazine as the selection of BTK inhibitor
EP3812387A1 (en) 2011-07-21 2021-04-28 Sumitomo Dainippon Pharma Oncology, Inc. Heterocyclic protein kinase inhibitors
BR112014009276A8 (en) * 2011-10-19 2017-06-20 Pharmacyclics Inc use of bruton tyrosine kinase inhibitors (btk)
EP2770830A4 (en) 2011-10-28 2015-05-27 Celgene Avilomics Res Inc Methods of treating a bruton's tyrosine kinase disease or disorder
DK2786996T3 (en) 2011-11-29 2016-12-19 Ono Pharmaceutical Co Hydrochloride PURINONDERIVAT
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014004707A1 (en) * 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
MX2015001081A (en) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk).
LT3181567T (en) 2012-09-10 2019-07-25 Principia Biopharma Inc. Pyrazolopyrimidine compounds as kinase inhibitors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EA201591051A1 (en) 2013-02-08 2016-06-30 Селджен Авиломикс Рисерч, Инк. ERK INHIBITORS AND THEIR OPTIONS
EP2970205B1 (en) 2013-03-14 2019-05-08 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
RU2019134551A (en) * 2013-05-30 2019-11-22 Инфинити Фармасьютикалз, Инк. TREATING MALIGNANT TUMORS USING MODULATORS OF PI3-KINASE ISOFORM
WO2015023703A1 (en) 2013-08-12 2015-02-19 Pharmacyclics, Inc. Methods for the treatment of her2 amplified cancer
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
JP2016536354A (en) * 2013-10-10 2016-11-24 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． HDAC inhibitors alone or in combination with BTK inhibitors for the treatment of non-Hodgkin lymphoma
TWI620565B (en) 2013-10-25 2018-04-11 製藥公司 Methods of treating and preventing graft versus host disease
ES2717777T3 (en) * 2013-11-06 2019-06-25 Mayo Found Medical Education & Res Methods and materials for treating hematological malignancies
CN105792846A (en) * 2013-11-07 2016-07-20 豪夫迈·罗氏有限公司 Combination therapy of an anti CD20 antibody with a BTK inhibitor
WO2015071432A1 (en) * 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
WO2015084892A1 (en) * 2013-12-02 2015-06-11 Cornell University Methods for treating b cell proliferative disorders
BR112016012794A2 (en) 2013-12-05 2017-08-08 Acerta Pharma Bv THERAPEUTIC COMBINATION OF A PI3K INHIBITOR AND A BTK INHIBITOR
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
MX2016010754A (en) 2014-02-21 2017-03-03 Principia Biopharma Inc Salts and solid form of a btk inhibitor.
US20150238490A1 (en) * 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2015146159A1 (en) 2014-03-25 2015-10-01 Ono Pharmaceutical Co., Ltd. Prophylactic agent and/or therapeutic agent for diffuse large b-cell lymphoma
CA2940671A1 (en) * 2014-04-07 2015-10-15 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
US9937171B2 (en) 2014-04-11 2018-04-10 Acerta Pharma B.V. Methods of blocking the CXCR-4/SDF-1 signaling pathway with inhibitors of bruton's tyrosine kinase
WO2015185998A2 (en) * 2014-04-11 2015-12-10 Acerta Pharma B.V. Methods of blocking the cxcr-4/sdf-1 signaling pathway with inhibitors of bone marrow x kinase
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
CN104825455B (en) * 2014-06-11 2017-08-15 中国科学院合肥物质科学研究院 The purposes of Buddhist nun is replaced according to Shandong
US20150361504A1 (en) * 2014-06-13 2015-12-17 Pharmacyclics Llc Biomarker for predicting response of cll to treatment with a btk inhibitor
US9949971B2 (en) 2014-06-17 2018-04-24 Acerta Pharma B.V. Therapeutic combinations of a BTK inhibitor, a PI3K inhibitor and/or a JAK-2 inhibitor
WO2016010961A1 (en) * 2014-07-15 2016-01-21 Abbvie Inc. Enzyme occupancy assay
US20160022684A1 (en) * 2014-07-25 2016-01-28 Pharmacyclics Llc Bet inhibitor and bruton's tyrosine kinase inhibitor combinations
US20160032404A1 (en) * 2014-08-01 2016-02-04 Pharmacyclics Llc Biomarkers for predicting response of dlbcl to treatment with a btk inhibitor
BR112017002232A2 (en) * 2014-08-08 2018-07-24 Janssen Pharmaceutica Nv bruton tyrosine kinase inhibitor combinations and uses thereof
SI3179991T1 (en) 2014-08-11 2022-04-29 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a bcl-2 inhibitor
ES2741785T3 (en) 2014-08-13 2020-02-12 Celgene Car Llc Forms and compositions of an ERK inhibitor
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN104873515B (en) * 2014-10-30 2017-04-05 中国科学院合肥物质科学研究院 The application of acute leukemia FLT3 ITD being mutated for Buddhist nun according to Shandong
WO2016071770A2 (en) * 2014-11-05 2016-05-12 Janssen Pharmaceutica Nv Biological markers for identifying ibrutinib resistance in patients having mantle cell lymphoma and methods of using the same
CN104407067B (en) * 2014-11-17 2016-01-20 广东东阳光药业有限公司 The detection method of Buddhist nun and isomeride thereof is replaced according to Shandong
WO2016090255A1 (en) * 2014-12-05 2016-06-09 Sriram Balasubramanian Biological markers for predicting responsiveness to ibrutinib and r-chop combination therapy and methods of using the same
SG11201704808VA (en) 2014-12-18 2017-07-28 Principia Biopharma Inc Treatment of pemphigus
AU2015369665A1 (en) * 2014-12-23 2017-06-29 Pharmacyclics Llc BTK inhibitor combinations and dosing regimen
US20180193274A1 (en) * 2014-12-24 2018-07-12 Principia Biopharma Inc. Compositions for ileo-jejunal drug delivery
IL295941A (en) * 2015-04-06 2022-10-01 Janssen Pharmaceutica Nv Compositions containing ibrutinib
US10239879B2 (en) 2015-04-09 2019-03-26 Ono Pharmaceutical Co., Ltd. Process for producing purinone derivative
JP6823587B2 (en) 2015-04-13 2021-02-03 第一三共株式会社 Combination therapy with MDM2 inhibitor and BTK inhibitor
KR101776238B1 (en) * 2015-06-12 2017-09-12 사회복지법인 삼성생명공익재단 Ibrutinib sensitivity related genes in patients with glioblastoma multiforme and Use Thereof
TW201718572A (en) 2015-06-24 2017-06-01 普林斯匹亞生物製藥公司 Tyrosine kinase inhibitors
MX2020014163A (en) 2015-07-02 2022-09-29 Acerta Pharma Bv Solid forms and formulations of (s)-4-(8-amino-3-(1 -(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(py ridin-2-yl)benzamide.
MA44909A (en) * 2015-09-15 2018-07-25 Acerta Pharma Bv THERAPEUTIC ASSOCIATION OF A CD19 INHIBITOR AND A BTK INHIBITOR
MA43650A (en) * 2016-01-19 2018-11-28 Janssen Pharmaceutica Nv FORMULATIONS / COMPOSITIONS INCLUDING A BTK INHIBITOR
US11813261B2 (en) 2016-04-19 2023-11-14 Acetylon Pharmaceuticals, Inc. HDAC inhibitors, alone or in combination with BTK inhibitors, for treating chronic lymphocytic leukemia
SG10201912456RA (en) 2016-06-24 2020-02-27 Infinity Pharmaceuticals Inc Combination therapies
JP7109007B2 (en) * 2016-06-27 2022-07-29 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Cancer treatment combination
IL293621B2 (en) 2016-06-29 2023-09-01 Principia Biopharma Inc Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile
CA3040840A1 (en) 2016-10-17 2018-04-26 Daiichi Sankyo Company, Limited Combined use of mdm2 inhibitor and dna methyltransferase inhibitor for cancer treatment
CN108069974B (en) * 2016-11-15 2019-12-10 杭州和正医药有限公司 Selective Bruton tyrosine kinase inhibitor and application thereof
BR112020020246A8 (en) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc AXL KINASE INHIBITORS AND THEIR USE
CA3095580A1 (en) 2018-04-13 2019-10-17 Sumitomo Dainippon Pharma Oncology, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
CN112512597A (en) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 Methods for treating diseases associated with aberrant ACVR1 expression and ACVR1 inhibitors useful therefor
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
JP2022526713A (en) 2019-03-21 2022-05-26 オンクセオ Dbait molecule in combination with a kinase inhibitor for the treatment of cancer
JP2022527505A (en) * 2019-03-28 2022-06-02 カーディフ・オンコロジー・インコーポレイテッド PLK1 Inhibitors and PSA Levels for Prostate Cancer
CN114761006A (en) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) Methods of treating cancer resistant to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
CA3200332A1 (en) * 2020-12-02 2022-06-09 Telios Pharma, Inc. Methods and compositions for treating an ophthalmic condition
CN114681459B (en) * 2020-12-29 2024-02-27 上海云晟研新生物科技有限公司 Ibutenib pharmaceutical composition, preparation method and application thereof
WO2023133444A1 (en) * 2022-01-07 2023-07-13 University Of Florida Research Foundation, Incorporated Bruton's tyrosine kinase inhibitors as antiviral agents

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002012188A2 (en) * 2000-08-09 2002-02-14 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
HUE031334T2 (en) * 2006-09-22 2017-07-28 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN101475632B (en) * 2008-01-03 2012-01-04 张喜田 Recombinant Ganoderma lucidum immunoregulation protein with antineoplastic function and medicinal preparation thereof
US20100160322A1 (en) * 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (en) * 2008-12-04 2015-04-10 APOPTOZINDUCE FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTO-IMMUNE DISEASES
US8299077B2 (en) * 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
CN105616402A (en) * 2010-03-08 2016-06-01 光谱医药公司 Thioxanthone-based autophagy inhibitor therapies to treat cancer
CN107898791A (en) * 2010-06-03 2018-04-13 药品循环有限责任公司 The application of bruton's tyrosine kinase (BTK) inhibitor
BR112014009276A8 (en) * 2011-10-19 2017-06-20 Pharmacyclics Inc use of bruton tyrosine kinase inhibitors (btk)

Also Published As

Publication number Publication date
EA032463B1 (en) 2019-05-31
JP2019151651A (en) 2019-09-12
KR20190138703A (en) 2019-12-13
CA2851808C (en) 2021-04-13
WO2013059738A2 (en) 2013-04-25
EP2771010A4 (en) 2015-04-01
JP2024020199A (en) 2024-02-14
MX2014004647A (en) 2014-11-10
JP2014530877A (en) 2014-11-20
BR112014009276A2 (en) 2017-06-13
CN110801454A (en) 2020-02-18
IL272622A (en) 2020-03-31
IL232059A0 (en) 2014-05-28
JP6909255B2 (en) 2021-07-28
JP6506555B2 (en) 2019-04-24
US20140303191A1 (en) 2014-10-09
IL288009A (en) 2022-01-01
SG11201401625TA (en) 2014-05-29
AU2012325804A1 (en) 2014-05-01
EA201490798A1 (en) 2015-02-27
KR20140077208A (en) 2014-06-23
MX361772B (en) 2018-12-17
US20170266186A1 (en) 2017-09-21
KR20230109775A (en) 2023-07-20
JP2018024686A (en) 2018-02-15
AU2012325804B2 (en) 2017-09-07
AU2021286264A1 (en) 2022-01-06
CA2851808A1 (en) 2013-04-25
US20210361657A1 (en) 2021-11-25
KR102054468B1 (en) 2019-12-11
AU2019229398A1 (en) 2019-10-03
CN104039325A (en) 2014-09-10
JP7366084B2 (en) 2023-10-20
AU2017272271A1 (en) 2018-01-04
AU2019229398B2 (en) 2021-09-16
EA201892766A1 (en) 2019-08-30
CA3110966A1 (en) 2013-04-25
KR20210065203A (en) 2021-06-03
IL232059B (en) 2020-02-27
EP2771010A2 (en) 2014-09-03
JP6588515B2 (en) 2019-10-09
KR102258778B1 (en) 2021-06-02
BR112014009276A8 (en) 2017-06-20
JP2021169468A (en) 2021-10-28

Similar Documents

Publication Publication Date Title
IL288009A (en) Use of inhibitors of bruton's tyrosine kinase (btk)
ZA202105174B (en) Crystalline forms of a bruton's tyrosine kinase inhibitor
ZA201400012B (en) Inhibitors of bruton's tyrosine kinase
ZA201308397B (en) Inhibitors of bruton's tyrosine kinase
ZA201209381B (en) The use of inhibitors of bruton's tyrosine kinase (btk)
ZA201400739B (en) Inhibitors of bruton's tyrosine kinase
EP2925740A4 (en) Inhibitors of bruton's tyrosine kinase
ZA201300705B (en) Inhibitors of bruton's tyrosine kinase
IL238571A0 (en) Bruton's tyrosine kinase inhibitors
EP2858500A4 (en) Inhibitors of bruton's tyrosine kinase
IL244492A0 (en) Inhibitors of bruton's tyrosine kinase
IL236495A0 (en) Heteroaromatic compounds as bruton's tyrosine kinase (btk)inhibitors
HK1200449A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases bub1
ZA201301679B (en) Inhibitors of bruton's tyrosine kinase
ZA201202552B (en) Inhibitors of bruton's tyrosine kinase
EP2809673A4 (en) Cyclic molecules as bruton's tyrosine kinase inhibitors